Merriman Curhan Ford downgrades Depomed, Inc. (Nasdaq: DEPO) from Buy to Neutral, saying "Surprise Rejection of Xenoport (Nasdaq: XNPT) Drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE